JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Not yet recruiting	Phase 2	2024-12-12		NCT06731153

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fudan University	653

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Breast cancer institute of Fudan University Cancer Hospital	Shanghai	China	16

Clinical trials